Biolase, Inc – ‘10-Q’ for 3/31/15 – ‘EXCEL’

On:  Friday, 5/1/15, at 4:06pm ET   ·   For:  3/31/15   ·   Accession #:  1564590-15-3181   ·   File #:  1-36385

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    423K 
 2: EX-10.1     Material Contract                                   HTML     67K 
 3: EX-10.3     Material Contract                                   HTML     55K 
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     27K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     27K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
 7: EX-32.2     Certification -- §906 - SOA'02                      HTML     21K 
47: R1          Document and Entity Information                     HTML     42K 
37: R2          Consolidated Balance Sheets (Unaudited)             HTML    129K 
45: R3          Consolidated Balance Sheets (Unaudited)             HTML     49K 
                (Parenthetical)                                                  
49: R4          Consolidated Statements Of Operations And           HTML    102K 
                Comprehensive Loss (Unaudited)                                   
64: R5          Consolidated Statements Of Cash Flows (Unaudited)   HTML    141K 
39: R6          Description of Business and Basis of Presentation   HTML     31K 
44: R7          Summary of Significant Accounting Policies          HTML     34K 
34: R8          Stock-Based Awards and Per Share Information        HTML    187K 
26: R9          Inventory                                           HTML     41K 
65: R10         Property, Plant, and Equipment                      HTML     60K 
51: R11         Intangible Assets and Goodwill                      HTML    112K 
50: R12         Accrued Liabilities and Deferred Revenue            HTML     95K 
55: R13         Lines Of Credit and Other Borrowings                HTML     35K 
56: R14         Commitments and Contingencies                       HTML     48K 
54: R15         Segment Information                                 HTML     46K 
57: R16         Concentrations                                      HTML     50K 
46: R17         Income Taxes                                        HTML     29K 
48: R18         Subsequent Event                                    HTML     24K 
53: R19         Accounting Policies (Policies)                      HTML     64K 
69: R20         Stock-Based Awards and Per Share Information        HTML    190K 
                (Tables)                                                         
60: R21         Inventory (Tables)                                  HTML     39K 
41: R22         Property, Plant, and Equipment (Tables)             HTML     58K 
52: R23         Intangible Assets and Goodwill (Tables)             HTML    106K 
43: R24         Accrued Liabilities and Deferred Revenue (Tables)   HTML     98K 
20: R25         Segment Information (Tables)                        HTML     39K 
61: R26         Concentrations (Tables)                             HTML     48K 
66: R27         Description of Business and Basis of Presentation   HTML     32K 
                - Additional Information (Detail)                                
30: R28         Summary of Significant Accounting Policies -        HTML     24K 
                Additional Information (Detail)                                  
29: R29         Stock-Based Awards and Per Share Information -      HTML    142K 
                Additional Information (Detail)                                  
32: R30         Classification of Compensation Expense Associated   HTML     37K 
                with Share-Based Payments (Detail)                               
33: R31         Assumptions Used in Estimating Fair Value of Stock  HTML     30K 
                Options Granted (Detail)                                         
35: R32         Summary of Option Activity (Detail)                 HTML     79K 
18: R33         Cash Proceeds Along with Fair Value Disclosures     HTML     37K 
                Related to Grants, Exercises, and Vested Options                 
                (Detail)                                                         
58: R34         Summary of Warrant Activity (Detail)                HTML     39K 
40: R35         Components of Inventory (Detail)                    HTML     33K 
42: R36         Inventory - Additional Information (Detail)         HTML     24K 
23: R37         Summary of Property, Plant, and Equipment (Detail)  HTML     53K 
68: R38         Property, Plant, and Equipment - Additional         HTML     26K 
                Information (Detail)                                             
14: R39         Intangible Assets and Goodwill - Additional         HTML     26K 
                Information (Detail)                                             
36: R40         Intangible Assets and Related Accumulated           HTML     57K 
                Amortization (Detail)                                            
63: R41         Components of Accrued Liabilities (Detail)          HTML     51K 
22: R42         Changes in Initial Product Warranty Accrual and     HTML     39K 
                Expenses Under Initial and Extended Warranties                   
                (Detail)                                                         
28: R43         Accrued Liabilities and Deferred Revenue -          HTML     25K 
                Additional Information (Detail)                                  
31: R44         Summary of Deferred Revenue (Detail)                HTML     29K 
38: R45         Lines of Credit and Other Borrowings - Additional   HTML     87K 
                Information (Detail)                                             
17: R46         Commitments and Contingencies - Additional          HTML    111K 
                Information (Detail)                                             
25: R47         Segment Information - Additional Information        HTML     41K 
                (Detail)                                                         
15: R48         Summary of Net Revenue by Geographic Location       HTML     28K 
                (Detail)                                                         
62: R49         Concentrations - Summary of Net Revenue from        HTML     41K 
                Various Products (Detail)                                        
21: R50         Concentrations - Additional Information (Detail)    HTML     33K 
59: R51         Income Taxes - Additional Information (Detail)      HTML     34K 
24: R52         Subsequent Event - Additional Information (Detail)  HTML     38K 
67: XML         IDEA XML File -- Filing Summary                      XML    101K 
16: EXCEL       IDEA Workbook of Financial Reports                  XLSX    116K 
27: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS   1.10M 
 8: EX-101.INS  XBRL Instance -- biol-20150331                       XML   1.39M 
10: EX-101.CAL  XBRL Calculations -- biol-20150331_cal               XML    140K 
11: EX-101.DEF  XBRL Definitions -- biol-20150331_def                XML    333K 
12: EX-101.LAB  XBRL Labels -- biol-20150331_lab                     XML    975K 
13: EX-101.PRE  XBRL Presentations -- biol-20150331_pre              XML    695K 
 9: EX-101.SCH  XBRL Schema -- biol-20150331                         XSD    147K 
19: ZIP         XBRL Zipped Folder -- 0001564590-15-003181-xbrl      Zip    114K 

‘EXCEL’   —   IDEA Workbook of Financial Reports

This is an IDEA Workbook.

Download this Microsoft® Excel® .xlsx workbook

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/31/21  Biolase, Inc.                     10-K       12/31/20   88:15M                                    ActiveDisclosure/FA
12/08/20  Biolase, Inc.                     S-1/A                  3:585K                                   Donnelley … Solutions/FA